My name is Dr. H. George Mandel, and I am currently a Professor of Pharmacology where I devote my time to research and teaching. For much of my career, I have served as the Departmental Chair. Presently, my major contacts are with medical students that participate in our principal pharmacology course. Also, I participate in “Problem Based Learning,” which are small group conferences where clinical problems are discussed with first and second year medical students. Furthermore, I organize a clinical pharmacology discussion group elective for senior medical students.
I no longer have my own research program, but I continue to assist younger faculty members, such as Dr. Travis O'Brien, on their research funded toxicology projects. Most recently these projects have involved the interactions of chromium with mammalian DNA to elucidate the mechanism of the metal's carcinogenic and other toxic actions. Last, I am currently the Chairman of the National Caucus of Basic Biomedical Science Chairs, where we discuss with our national political leaders two major concerns: the importance of health research and the need for NIH to achieve a realistic budget that that will aid in improving the health of our citizens.
BIOGRAPHICAL SKETCH
| Education and Training |
Degree |
Year |
Field of Study |
| Yale University, New Haven, CT |
B.S. |
1944 |
Chemistry |
| Yale University, New Haven, CT |
Ph.D. |
1949 |
Organic Chemistry |
| MRC Toxicology, Carshalton, England |
- |
1986 |
Carcinogenesis |
| University College, London, England |
- |
1993 |
Molecular Biology |
PROFESSIONAL EXPERIENCE
The George Washington University School of Medicine, Department of Pharmacology
Research Associate, 1949-50
Assistant Research Professor, 1950-52
Associate Professor, 1952-58
Professor, 1958 – present
Chairman, 1960-1996
FELLOWSHIPS RECEIVED FOR RESEARCH
Commonwealth Fund Fellow, Cambridge University, England, 8 months, 1956 (Biochemistry)
Commonwealth Fund Fellow, University of Auckland, New Zealand, 7 months, 1964 (Molecular Virology)
American Cancer Society, Eleanor Roosevelt International Fellow, 12 months, 1970-71, Chester Beatty Research Institute, London, England (Cancer Chemotherapy)
American Cancer Society Scholar in Cancer Research, 12 months, 1978-79, UC Medical Center, San Francisco, CA (Clinical Pharmacology)
Burroughs Wellcome Travel Grant, MRC Toxicology Laboratories, Carshalton, England, 1 month, 1988
(Carcinogenesis)
International Canc. Res. Technol. Transfer Award, International Union Against Cancer, Lyon, France, 1989 (Carcinogenesis)
HONORS
John J. Abel Award in Pharmacology (sponsored by Eli Lilly and Co.), 1958
Distinguished Achievement Award, Washington Academy of Sciences, 1958
Member Editorial Board,, J. Pharmacol & Exptl. Therap, 1960-65, Field Editor for Chemotherapy, 1978-94
Member Editorial Board, Molecular Pharmacology, 1965-69; Cancer Research, 1974-76, Assoc. Ed., 1977-81
Res. Comm. Chem. Path & Pharmacology, 1972-98; Cancer Drug Deliv., 1983-92
Who's Who in America, 1966-
Golden Apple Teaching Award, Student American Medical Association, 1969, 1985, 1997
President, American Society for Pharmacology and Experimental Therapeutics, 1973-74
President, Association for Medical School Pharmacology, 1976-78
Chairman, Cancer Special Program Advisory Committee, (Study Section), National Cancer Institute, 1976-78
Chairman, National Caucus of Basic Biomedical Science Chairs, 1991-
Honorary Research Fellow, Biochemistry/Molecular Biology, University College London, 1993-
Secretary, Citizens for Public Research (CPR) and Education Funding, 1996-99
The George Washington Award, George Washington Univ., 1998
Member, Society of Distinguished Teachers, George Washington University School of Medicine, 2001
Listing, Outstanding People of the 20 th Century, Intl. Biograph.. Centre, Cambridge, England, 2001
GRADUATE STUDENT MENTORING
Director, 13 Ph.D. candidates, including 1 Nobel Prize winner; 6 M.S. candidates
As Departmental Chairman, responsible for more than 100 successful Ph.D. candidates, some 25 M.S. students
RESEARCH GRANT REVIEW PANELS
Pharmacology B Study Section, USPHS, 1963-68
Chemotherapy and Clinical Investigations Committees, American Cancer Society, 1969-73
Cancer Research Training Committee, National Cancer Institute, 1971-73
Advisory Committee to Army Research Office, NAS-NRC, 1973-76
Cancer Special Program Advisory Committee, National Cancer Institute, 1974-78, Chairman, 1976-78
Drug Abuse Research Review Committee, National Institute on Drug Abuse ( ad hoc member), 1974-78
Medical Research Service Merit Review in Alcohol.and Drug Depend. (Clinical Pharmacology) Vet. Admin, 1975-78
National Large Bowel Cancer Project Working Cadre, National Cancer Institute, 1980-84
US- Israel Binational Science Foundation, 1986-2001
SELECTED PEER-REVIEWED RESEARCH PUBLICATIONS
Mandel, H.G., and Smith, P.K. A note on the synthesis of 14 C carboxyl-labeled salicylic acid. J. Am. Pharm. Assn., 3 :479 (1950).
Maybaum, J. and Mandel, H.G. Unilateral Chromatid Damage: A new basis for 6-thioguanine cytotoxicity. Cancer Res. 43:3852-3856 (1983).
Loeb, A.L., Mandel, H.G., Straw, J.A., and Bean, B.L. Increased aortic DNA synthesis precedes renal hypertension in rats: an obligatory step? Hypertension, 8:754-761 (1986).
Pieper, R.O., Barrows, L.R. and Mandel, H.G. Correlation of biochemical effects and incorporation of 3-deazaguanine into nucleic acids to cytotoxicity in L1210 cells. Cancer Res., 46:4960-4965 (1986).
Mandel, H.G., Manson, M.M., Judah, D.J., Simpson, J.L., Green, J.A., Forrester, L.M., Wolf, C.R., and Neal, G.E. Metabolic basis for the protective effect of the antioxidant ethoxyquin on aflatoxin B 1 hepatocarcinogenesis in the rat. Cancer Res., 47:5218-5332 (1987).
Pieper, R.O., Kennedy, K.A., and Mandel, H.G. DNA-directed actions of 3-Deazaguanine: Effects on DNA integrity and DNA elongation / ligation. Cancer Res., 48:2774-2778 (1988).
Pieper, R.O., and Mandel, H.G. Interrelationship of 3-deazaguanine-induced growth inhibitory actions in L1210 cells. Biochem. Pharmacol., 37:3534-3537 (1988).
Mandel, H.G., Straw, J.A., Farmer, P.B. and Martin, J. Chromatographic detection of 7-methyladenine in urine of rats administered N-methylnitrosourea: a potential marker for monitoring exposure to methylating carcinogens. Carcinogenesis, 10:757-762 (1989).
Mandel, H.G., Straw, J.A., Greene, P.S., and Richardson, D.C. Urinary O 6 -methylguanine excretion in the rat after O 6 -methylguanine but not N-methylnitrosourea administration. Research Communications in Chem. Path. and Pharmacol. 66:269-286 (1989).
Mandel,H.G., Judah, D.J. and Neal, G.E. Effect of Dietary Protein Level on Aflatoxin B 1 Actions in the Liver of Weanling Rats. Carcinogenesis, 13:1853-1857 (1992).
Mandel, H.G., Kusmierz, J.J., Dickens, B.F., and Anderson, L.W. Quantitation of urinary 7-methyladenine by gas chromatography - mass spectrometry using isotopically labeled standards. Anal. Biochem. 217:292-297 (1994).
Mandel, H.G., Straw, J.A., Wenger, L.J., and Kusmierz, J.J. The excretion of 7-methyladenine in the urine of rats exposed to carcinogenic methylating agents. Carcinogenesis 15:1393-98 (1994).
Mandel, H.G. Chloramphenicol Acetyltransferase (CAT): Assay Revisions Required. Anal. Biochem. 230:191-193 (1995).
Riley, J., Mandel, H.G., Sinha, S., Judah, D.J. and Neal, G.E. In vitro Inactivation of the human Harvey-ras proto-oncogene by Aflatoxin Bl. Carcinogenesis 18 , 905-910 (1997).
Stanley, L.A.,Mandel, H.G., Riley, J., Sinha, S., Higginson, F.M., Judah, D.J. and Neal, G.E. Mutations associated with in vivo aflatoxin B 1 induced carcinogenesis need not be present in the in vitro transformation by this toxin. Cancer Letters 137:173-181 (1999).
Fernandez, P.M. and Mandel, H.G. Enhancing quantification of mammalian cell transfections with chloramphenicol acetyltransferase reporter plasmids. J. Biochem. Biophys. Methods 46:107-111 (2000).
Mandel, H.G. Update on caffeine: Consumption, disposition and action. Food and Chemical Toxicol., 40:1231-1234 (2002).
O'Brien, T., Mandel, H.G., Pritchard, D.E. and Patierno, S.R. Critical role of chromium (Cr)-DNA interactions in the formation of Cr-induced polymerase arresting lesions. Biochemistry, 41:12529-12537 (2002).
Mandel, H.G. and Vesell, E.S. From progress to regression: biomedical research funding. J. Clinical Investigation, 114, 872-878, (2004).
SELECTED REVIEWS AND CHAPTERS
Mandel, H.G., The physiological disposition of some anticancer agents. Pharmacological Reviews, 11:743-838 (1959).
Mandel, H.G., The incorporation of 5-fluorouracil into RNA and its molecular consequences, in Progress In Molecular and Subcellular Biology , F.E. Hahn, Ed., Springer, New York, (1969), pp. 82-135.
La Du, B.N., Mandel, H.G. and Way, E.L., eds, Fundamentals of Drug Metabolism and Drug Disposition , Williams and Wilkins Co., Baltimore, 615 pp. (1971).
Mandel, H.G., Basic aspects of chemotherapy for gynecologic cancer, in Gynecologic Oncology , L. McGowan, Ed., Appleton Century Crofts, N.Y., (1978), pp. 89-147.
Mandel, H.G. and Cohn, V.H., Fat-soluble Vitamins. Goodman & Gilman's The Pharmacological Basis of Therapeutics , 7th Edition, A.G. Gilman, L.S. Goodman, T.W. Rall and F. Murad, Eds., Macmillan Co., N.W., Chapter 67, (1985), pp.1573-1591.
Mandel, H.G. Effects of older age on drug action, in Enhancers of Performance and Endurance , C.J. Carr and E. Jokl, Eds., Earlbaum Associates, Inc., Hillsdale, N.J., Chap. 1, (1986), pp. 1-51.
Loo, T.L., Freireich, E.J. and Mandel, H.G., Pharmacology of cancer chemotherapeutic and immunotherapeutic agents, with comments on the effects of age, in Handbook of Pharmacology of Aging , 2nd Edition, Roberts J., Snyder D.L. and Friedman, E., Eds. CRC Press, Boca Raton, FL, (1996), pp. 311-339.
OTHERS
Vesell, E.S. and Mandel, H.G. Crisis in NIH Funding (Letter). Science 215 :1026-1028 (1982).
Mandel, H.G. Funding More NIH Research Grants. Science 221 :338-340 (1983).
Mandel, H.G., and Vesell, E.S. NIH Funding, Letter to the Editor. FASEB J. 3:2322-3 (1989).
Vesell, E.S., Mandel, H.G., Brody, T.M., Greenbaum, L.M., Roberts, J., and Standaert, F.G. Vacant Chairs of Pharmacology: A Committee Report. Academic Medicine 66:93 (1991).
Mandel, H.G., Woosley, R.L, and Vesell, E.S. Biomedical Research Funding: View of the National Caucus of Basic Biomedical Science Chairs, Editorial. FASEB J. 6:3133-3134 (1992).
Mandel, H.G., on behalf of the members of the National Caucus of Basic Biomedical Science Chairs. The R.W. Johnson Report: Misguided reform of the basic sciences curriculum, Letter to the Editor. Academic Medicine 68:202 (1993).
Mandel, H.G., Funding of Newly Submitted NIH Grant Applications. Letter to the Editor. Science, 266:1789 (1994).
Mandel, H.G., Funding of NIH Grant Applications: Update. Letter to the Editor. Science, 269:13-14 (1995).
Mandel, H.G. and the NCBBS., Downsizing of Basic Science Departments in U.S. Medical Schools: Perceptions of their Chairs. Academic Medicine 72 , 894-900 (1997).
Mandel, H.G. and Vesell, E.S. Likelihood of NIH extramural funding. Letter, Science Compass. Science, 285:1674-1676 (1999).
Mandel, H.G. and Vesell, E.S. NIH budgets grow, but not R01 success rates. Letter, Science Compass, Science 294: 53-57 (2001).
RESEARCH FUNDING
Since 1996, None
Before that, continuous research support, as well as training grants from NIH, ACS, ILSI, etc., 1957 - 1995
